<DOC>
	<DOCNO>NCT01390428</DOCNO>
	<brief_summary>This study compare pharmacokinetics ( PK ) grazoprevir ( MK-5172 ) administer participant mild , moderate severe hepatic insufficiency ( assessed criterion Child-Pugh 's scale ) PK grazoprevir administer healthy participant .</brief_summary>
	<brief_title>Study Investigate Influence Hepatic Insufficiency Pharmacokinetics Grazoprevir ( MK-5172-013 )</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatic Insufficiency</mesh_term>
	<criteria>If female , must nonchildbearing potential willing use least 2 acceptable method contraception enrollment 2 week last dose study drug No clinically significant abnormality electrocardiogram Hepatic Insufficiency Participants Only : Other hepatic insufficiency feature cirrhosis , otherwise good health base medical history , physical examination , vital sign , laboratory safety test Chronic ( &gt; 6 month ) , stable ( acute episode illness within previous 2 month due deterioration hepatic function ) hepatic insufficiency feature cirrhosis due etiology Score ChildPugh scale must range 5 6 ( mild hepatic insufficiency ) 7 9 ( moderate hepatic insufficiency ) 10 15 ( severe hepatic insufficiency ) Matched Healthy Participants Only : In good health base medical history , physical examination , vital sign , laboratory safety test History illness might confound result study pose additional risk participant History clinically significant endocrine , gastrointestinal ( related hepatic impairment ) , cardiovascular , hematological , immunological , renal , respiratory , genitourinary abnormality diseases Pregnancy Estimated creatinine clearance â‰¤60 mL/min History stroke , chronic seizure , major neurological disorder History neoplastic disease ( include leukemia , lymphoma , malignant melanoma ) , myeloproliferative disease , regardless time since treatment Unable refrain anticipates use medication , include prescription nonprescription drug herbal remedy ( St. John 's Wort , green tea , gingko , coenzyme Q , ginseng , echinacea , etc . ) nutritional supplement ( e.g. , garlic supplement ) , begin approximately 2 week ( 5 halflives ) prior administration initial dose study drug , throughout study , poststudy visit Participated another investigational study within 4 week History significant multiple and/or severe allergy anaphylactic reaction significant intolerability prescription nonprescription drug food Hepatic Insufficiency Participants Only : Has history hepatitis C infection serology , regardless recent viral load status . Matched Healthy Participants Only : History chronic and/or active hepatic disease include elevation serum transaminase , hepatitis , biliary tract disease , history significant gastrointestinal surgery . History hepatitis C. Participants history selflimited hepatitis A complete resolution document least 6 month prior entry eligible inclusion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>